Latest News - Earnings and Financials

Tuesday, February 19, 2019

SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technology

SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is bein…

Read the full story

Tuesday, March 14, 2017

Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.

Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker:…

Read the full story

Thursday, June 16, 2016

Changes Afoot at Valeant Pharmaceuticals

Amid reports that its Obagi Medical Products and Solta Medical units  are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fi…

Read the full story

Wednesday, May 25, 2016

Robert Grant No Longer CEO of Alphaeon

Robert Grant is no longer CEO of Alphaeon, our sister site, has learned. After 3 years at the helm of the lifestyle healthcare company, Mr. Grant is relinquishing the leader…

Read the full story

Tuesday, February 23, 2016

Botox Helps Fuel Allergan’s “Better-Than-Expected” Q4 Earnings

Allergan is reporting “better-than-expected” fourth-quarter earnings, largely fueled by Botox. The company saw a 74 percent increase in Q4 net revenue to $4.2 Billion for Q4 2015, toppi…

Read the full story

Thursday, December 17, 2015

Valeant Issues Updated Financial Guidance

Valeant Pharmaceuticals International, Inc. announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016. "We are very excited abou…

Read the full story

Thursday, April 02, 2015

Novan Secures $50 Million Private Financing

Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscrib…

Read the full story

Monday, June 23, 2014

Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Update

Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial resul…

Read the full story

Monday, April 30, 2012

PhotoMedex Completes Sale of Common Stock for $40 Million

PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. T…

Read the full story